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Abstract
Pre-association of CD95 at the plasma membrane is mandatory for efficient death receptor signaling. This
homotrimerization occurs through self-association of an extracellular domain called the pre-ligand assembly domain
(PLAD). Using novel molecular and cellular tools, we confirmed that CD95-PLAD is necessary to promote CD95
multimerization and plays a pivotal role in the transmission of apoptotic signals. However, while a human CD95 mutant
deleted of the previously described PLAD domain (amino acids 1 to 66) fails to interact with its wild-type counterpart and
trigger autonomous cell death, deletion of amino acids 1 to 42 does not prevent homo- or hetero (human/mouse)-
oligomerization of CD95, and thus does not alter transmission of the apoptotic signal. Overall, these findings indicate that
the region between amino acids 43 to 66 corresponds to the minimal motif involved in CD95 homotypic interaction and is
necessary to convey an efficient apoptotic signal. Interfering with this PLAD may represent a new therapeutic strategy for
altering CD95-induced apoptotic and non-apoptotic signals.
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Introduction
Despite their pleiotropic effects, ranging from apoptosis to cell
proliferation, members of the TNF (Tumor Necrosis Factor)-
receptor family share remarkably similar structures and modes of
interaction and aggregation, indicating that subtle differences may
account for the transmission of different signaling pathways. CD95
(also known as Fas), a death receptor in the TNF-receptor family,
plays a crucial role in tumor surveillance, immune tolerance and
homeostasis, as evidenced by studies in human patients affected by
autoimmune lymphoproliferative syndrome (ALPS) type Ia [1–3].
The cognate ligand of CD95, CD95L, is a member of the TNF
superfamily primarily found on the surface of immune cells, where
it participates in the elimination of infected and transformed cells.
CD95 is a 319 amino acid type 1 transmembrane glycoprotein
containing three cysteine-rich domains (CRDs) in its extracellular
region and is predicted to form pre-assembled homotrimers, with
CRD2 and the upper part of CRD3 forming the region of
interaction with CD95L [4]. Upon binding of CD95L or agonistic
antibodies, the cytoplasmic portion of CD95 corresponding to the
death domain (DD) recruits the adaptor molecule Fas-associated
death domain protein (FADD) and the caspase-8 proenzyme,
leading to caspase activation and apoptosis (6–10).
Several studies have shown that CD95 splice variants with
truncated CRD2/CRD3 domains fail to interact with CD95L,
although they remain capable of dominantly interfering with the
CD95-mediated apoptotic signal [5–8]. This indicates that the first
sub-domain of CRD1 encompasses a minimal homotypic in-
teraction domain termed PLAD for pre-ligand assembly domain
[7] that contributes to self-association of the receptor [7,9].
Using novel molecular and cellular tools, we mapped the amino
acids necessary for efficient transmission of the CD95-mediated
apoptotic signal and demonstrated that the minimal domain
necessary for CD95 homotypic interaction corresponds to
a discrete region encompassed by amino acids 43 to 66.
Materials and Methods
Cells and Reagents
Agonistic IgM anti-human CD95 mAb clone 7C11, hamster
anti-mouse CD95 mAb clone JO2 and anti-human CD95 mAb
clone DX2 were purchased from BD Biosciences (Le Pont de
Claix, France). Rabbit polyclonal anti-CD95 (C20) was purchased
from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany).
Anti-HA mAb was from Eurogentec (Seraing, Belgium) and
monoclonal anti-DsRed was obtained from Clontech (Saint-
Germain-en-Laye, France). The metalloprotease-cleaved CD95L
(CD95L) and its multi-aggregated counterpart (Ig-CD95L) were
generated in our laboratory, as described previously [10,11].
Murine pro-B BaF3 cells [12] were maintained in RPMI 1640
containing 8% fetal calf serum (FCS), 2 mM glutamine and
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murine IL-3 produced in CHO cells transfected with a murine
IL3-encoding vector exactly as described previously [12]. CEM-
IRC (IRC for Ig-CD95L-Resistant) cells were obtained as described
previously [13] and maintained in RPMI1640 supplemented with
8% v/v heat-inactivated FCS and 2 mM L-glutamine at 37uC in
a 5% CO2 incubator. CEM-IRC and BaF3 cells (5.10
6 cells in
0.3 ml) were electroporated with 10 mg DNA at 200V/65 ms and
360V/10 ms, respectively, using the BTM 830 electroporation
generator (BTX, Holliston, MA). To select stable clones, CEM-
IRC cells were transfected and placed in a culture medium
supplemented with 0.8 mg/ml neomycin. Cells were then cloned
by limiting dilution and plasma membrane expression of CD95
was assessed by flow cytometry.
Plasmids Construction
The signal peptide (SP)-encoding sequence of CD95 (amino
acids 1 to 16; [14]) was amplified by PCR with a primer in which
the HA sequence tag has been added to the 59 end. This amplicon
was digested by HindIII/EcoRI and inserted into a pcDNA3-
(SPCD95HA) vector. The CD95 sequence lacking SP and
encompassing full-length CD95 or CD95 devoid of amino acids
1–42 or 1–66 were amplified by PCR using the following primer
pairs: cggaattcagattatcgtccaaaagtgttaatgc/cgaattcctagaccaagctttg-
gatttcatt (CD95 wild type), cggaattctgccataagccctgtcctccaggt/
cgaattcctagaccaagctttgtatttcatt (CD95(D1–42)), cggaattcgtgccctgc-
caagaagggaaggag/cgaattcctagaccaagctttgtatttcatt (CD95(D1–66)).
PCR products were digested with EcoRI and inserted into an
EcoRI-linearized pcDNA3-SPCD95HA vector. To generate the
CD95 construct devoid of the death domain, a premature stop
codon was inserted at amino acid position 210 using the primers
cgaaaacaattgagattatcgtccaaaagtgttaatgc/cggaattctcaatcagataaatt-
tattgccactgtttc. Next, the amplicons were digested with MfeI and
EcoRI and inserted in an EcoRI-linearized pcDNA3-PSCD95HA
vector. The chimeric CD95-gp130 construct corresponds to the
ectodomain of CD95 fused to the transmembrane and in-
tracellular regions of the IL-6 gp130 receptor. Extracellular
CD95 was isolated from the pEDr-wild-type CD95 plasmid by
XhoI/BamHI digestion and sub-cloned into a XhoI/BamHI-
cleaved pBluescript SK vector. Extracellular CD95 was digested
by XhoI/XbaI [15]. Using site-directed mutagenesis, a XbaI site
was created six nucleotides upstream of the transmembrane
domain of gp130 [16]. The pEDr vector encoding gp130 was then
cleaved using XhoI/XbaI digestion and the gp130 ectodomain
was replaced with the extracellular domain of CD95. CD95(1–42)-
, CD95(1–66)- and CD95(1–158)-mCherry constructs were
generated by amplifying the fragments 1–42, 1–66 and 1–158 of
CD95 using the primer pairs cggaattcctgggcatctggaccctccta/
ccgctcgaggaattggccatcatgatgcaggcc, cggaattcctgggcatctg-
gaccctccta/ccgctcgaggcagtctggttcatccccattg and cggaattcctggg-
catctggaccctccta/ccgctcgagcaagttagatctggatccttcctc, respectively.
PCR products were digested by EcoRI/XhoI and inserted into
an EcoRI/XhoI-linearized pcDNA3-(SPCD95HA) vector. Next,
mCherry was amplified from the pmCherry-1 Vector (Clontech)
using the primer pair gctctagagtgagcaagggcgaggaggac/gctctagat-
tacttgtacagctcgtccatgccg and the amplicon was digested by XbaI
and inserted in the reading frame with the extracellular regions of
CD95. To generate secreted mCherry, the mCherry sequence was
amplified using the primers cgggatccgtgagcaagggcgaggaggataac/
ccgctcgagttagaattccttgtacagctcgtccatgc, digested by BamHI/
EcoRI and inserted into the homemade vector pcDNA3-
(SPCD95Flag) encompassing the SP of CD95 fused with the Flag
tag. Each sequence was verified by sequencing (GATC, Mulhouse,
France).
Cell Death Assays
Cell viability was assessed by quantifying either the metabolic
activity (MTT assay) or the cell morphology (flow cytometry),
exactly as previously described [17,18]. In brief, 4.104 cells were
cultured for 16 hours in flat-bottom, 96-well plates with the
indicated concentrations of the apoptosis inducer in a final volume
of 100 ml. 15 ml of MTT (5 mg/ml in PBS) solution was added,
and after 4 hours of incubation at 37uC, the absorbance was
measured at 570 nm wavelength using the Titertek Labsystems
Multiskan reader (Turku, Finland).
Flow Cytometry Analysis
All steps were performed at 4uC. Cell membranes were
saturated with PBS/1% (w/v) BSA, washed with PBS and stained
with anti-CD95 mAb (clone DX2) or anti-HA mAb (clone HA.11)
for 30 min at 4uC. Cells were incubated for 30 min with a FITC-
conjugated secondary antibody and immediately analyzed using
a FACSCalibur (BD Bioscience).
Immunoblot Analysis
Cells were lyzed for 30 minutes at 4uC in lysis buffer (25 mM
HEPES pH 7.4, 1% v/v Triton X-100, 150 mM NaCl, 2 mM
EGTA supplemented with a mix of protease inhibitors (Sigma-
Aldrich)). Protein concentration was determined by the bicinch-
oninic acid method (PIERCE, Rockford, IL, USA) according to
the manufacturer’s protocol. Proteins were separated on 10 or
12% SDS-PAGE and transferred to a nitrocellulose membrane
(GE Healthcare, Buckinghamshire, England). The membrane was
blocked 15 minutes with TBST (50 mM Tris, 160 mM NaCl,
0.05% v/v Tween 20, pH 7.8) containing 5% w/v dried skimmed
milk (TBSTM). Primary antibody was incubated overnight at 4uC
in TBSTM. The membrane was intensively washed (TBST) and
then the peroxydase-labeled anti-rabbit (Zymed Laboratories, Inc,
San Francisco, CA, USA) or anti-mouse (GE Healthcare) was
added for 45 minutes. The proteins were visualized with the
enhanced chemiluminescence substrate kit (ECL, GE Healthcare).
Gel Filtration
CD95-mCherry constructs were secreted after calcium/phos-
phate-based transfection of HEK cells in serum-deprived Opti-
MEM (Life Technologies, Saint Aubin, France). Supernatants
were concentrated using centricon filters and resolved in Sephacryl
S-300 and S-200 High Resolution columns (GE Healthcare)
equilibrated with PBS. Using an A¨KTAprime plus apparatus (GE
Healthcare), proteins were eluted at a flow rate of 0.5 mL/min
and 60 fractions of 2 ml were harvested and analyzed by
immunoblot analysis with anti-DsRed mAb.
Results and Discussion
Initially described as the interleukin-6 (IL6) receptor, gp130 is
a transmembrane receptor capable of activation by a number of
cytokines, including IL6, IL11, leukemia inhibitory factor (LIF),
oncostatin M (OSM), and ciliary neurotrophic factor (CNTF) (for
review see [19]). A key feature of this receptor is that its
intracellular domain is pre-associated with Janus kinases (i.e., Jak1,
Jak2 and Tyk2), whose close proximity is required for activation by
trans-phosphorylation and the induction of STAT1/3 (signal
transducer and activator of Transcription)-mediated pro-pro-
liferative and survival pathways [20]. We postulated that if the
extracellular region of CD95 contains a homotypic interaction
motif that promotes pre-association of CD95 in a ligand-in-
dependent manner, fusion of this ectodomain to the intracellular
region of gp130 would elicit a pro-survival signal in the absence of
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CD95L binding. BaF3 cells constitute an ideal model system in
which to test this hypothesis, as they rely on IL3-mediated JAK/
STAT signaling for survival and proliferation [12]. These cells
were transiently transfected to express either gp130 devoid of the
extracellular domain (DExtra-gp130) [12] or the ectodomain of
CD95 fused to the transmembrane and intracellular regions of
gp130 (CD95-gp130) (Fig. 1A). As shown in Figure 1B, when
maintained in IL-3 deprived medium, no living cells expressing
DExtra-gp130 were detected. However, a population of CD95-
gp130 transfected BaF3 cells survived despite the absence of IL3.
To further confirm that the survival signal occurred through
CD95-gp130 expression, stable BaF3 clones expressing CD95-
gp130 were generated (Fig. 1C). In agreement with the results
observed following transient expression, BaF3 cells expressing
CD95-gp130 exhibited a basal proliferative rate in IL3-deprivated
medium, while all empty vector-transfected BaF3 cells died when
cultured in the absence of IL3. In addition, exposure to
homotrimeric CD95L (metalloprotease-cleaved CD95L, described
in [11]) significantly enhanced the viability of CD95-gp130-
expressing cells in a dose-dependent manner, while it failed to
enhance the survival of control cells (Fig. 1D). These findings
confirmed that the ectodomain of CD95 contains a homotypic
interaction domain necessary and sufficient to promote pre-
association of the death receptor (at least two molecules) and that
the magnitude of aggregation is increased and/or conformation is
altered upon binding of CD95L to CD95.
To identify the minimal region involved in CD95 self-
aggregation, we next examined the effect of wild-type and various
PLAD deletion mutants of CD95 [7] in a T-cell line expressing
a faint background of endogenous CD95 (CEM-IRC, see Fig. 2A
& 2B). Wild-type CD95 (CD95wild type) and mutants corresponding
to the truncation of amino acids 1 to 42 (CD95(D1–42)), 1 to 66
(CD95(D1–66)) or the intracellular DD (CD95(1–210)) were all
expressed at the expected molecular weight in the CEM-IRC
cells, as shown in Figure 2A. We next selected stable CEM-IRC
clones expressing CD95wild type, CD95(D1–42), CD95(D1–66) or
CD95(1–210) (Fig. 2B) and analyzed CD95-mediated apoptosis.
While the expression of wild-type CD95 restored CD95-mediated
apoptotic signaling in CEM-IRC cells exposed to Ig-CD95L or the
agonistic anti-CD95 antibody 7C11 (Fig. 2C), mutants that lacked
the DD or the complete CRD1 (CD95(1–210) and CD95(D1–66),
respectively) failed to transmit cell death signal (Fig. 2C).
Importantly, our data revealed that in a CD95-deficient
background, elimination of the first 42 amino acids of CD95 did
not affect the induction of apoptosis (Fig. 2C), contradicting
previous findings showing that this domain is mandatory for the
pre-association of CD95 and thus for transmission of the apoptotic
signal [7,9]. It is worth noting that deleting the entire CRD1
(amino acids 1 to 66) did not abolish 7C11 or CD95L binding
ruling out the possibility that CD95(D1–66) failed to transmit
apoptotic signaling due to a loss of its interaction with apoptosis
inducers (data not shown). These findings demonstrate that the
first 42 amino acids of CD95 are not crucial for CD95 function
and are therefore unlikely to contribute to its pre-association.
To further investigate the role of amino acids 1–42 in CD95
auto-aggregation, we developed a second cellular model. Because
mouse and human CD95 exhibit 49% sequence identity, we
hypothesized that the human CD95 PLAD could interact with its
murine counterpart to assemble trimeric receptors composed of
both human and mouse subunits. Accordingly, the apoptotic signal
induced by the agonistic anti-CD95 mAb JO2, which is only able
to bind and aggregate the mouse receptor, should be enhanced if
human CD95 associates with endogenous mouse CD95 and forms
a functional heterozygous complex (Fig. 3A). Human CD95wild type
and CD95(D1–42), CD95(D1–66) mutants were transfected into BaF3
cells and stable clones were isolated (Fig. 3B). BaF3 cells express
a minimal amount of endogenous mouse CD95 (data not shown)
and exhibit only weak sensitivity to JO2 (Fig. 3C). Ectopic
expression of human wild-type CD95 enhanced the JO2-induced
apoptotic signal, confirming that human and mouse CD95 can
form functional heteromultimers (Fig. 3C). By contrast, expression
of CD95(D1–66) did not modify the JO2-triggered apoptotic signal,
indicating that despite a propensity to auto-aggregate [21], the
intracellular DD of CD95 is not sufficient to form oligomers with
Figure 1. A chimeric CD95-gp130 construct confirms the presence of a PLAD in the CD95 ectodomain. A. The intracellular domain of
gp130 is pre-associated with JAK kinase. If the ectodomains of CD95 are pre-associated, the intracellular regions of a CD95-gp130 construct will be
brought in close proximity, inducing the trans-activation of JAKs and the implementation of a pro-survival signal. B. IL3-addicted BaF3 cells were
transfected with DExtra-gp130 or CD95-gp130. At 24 hours after transfection, living cells were incubated for 5 days with or without IL3. For each
condition, pictures were taken at 10x magnification. Images are representative of five pictures taken in different fields. C. BaF3 cells were transfected
with CD95-gp130 or empty vector (numbering indicates different clones). Stable clones were selected and the expression of CD95-gp130 was
assessed by flow cytometry. MTT assay was used to assess the cell viability of BaF3 cells in medium deprived of IL3. D. BaF3 cells were treated or
untreated with the indicated concentrations of cleaved CD95L in IL3-deprived medium and cell viability was quantified using MTT viability assay.
doi:10.1371/journal.pone.0046236.g001
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mouse CD95. In addition, it demonstrated that CRD1 encom-
passes a homotypic region that plays a pivotal role in pre-
association of CD95. Confirming our previous data and similar to
wild-type CD95, human CD95(D1–42) significantly enhanced the
JO2-driven apoptotic signal (Fig. 3C). This result indicates that the
region between amino acids 43 and 66 is instrumental in
oligomerization of CD95.
To confirm that the first 42 residues are not mandatory for pre-
association of the death receptor, we fused the full-length
ectodomain of CD95 (CD95(1–158)-mCherry), the complete
CRD1 region (CD95(1–66)-mCherry) or amino acids 1 to 42
(CD95(1–42)-mCherry) to a monomeric carrier (fluorescent pro-
tein mCherry; Fig. 4A) and the stoichiometry of each chimeric
protein was assessed by size-exclusion chromatography. After
transfection, HEK supernatants containing the different constructs
were fractionated in two gel filtration columns covering a resolu-
tion range for intermediate- (Sephacryl-300 HR with a fraction-
ation range comprised between 16104 and 1.56106 daltons)
(Fig. 4B & 4C) or low-molecular weight proteins (Sephacryl-200
HR with a fractionation range comprised between 56103 and
2.56105 daltons) (Fig. 4D & 4E). The estimated molecular mass of
the monomer for each recombinant protein is depicted in
Figure 4A. The complex formed by the ectodomain of CD95
fused to mCherry was eluted from the two columns as
a homotrimer (<145 kDa) (Fig. 4B–C–D–E). By contrast,
mCherry alone and CD95(1–42)-mCherry were resolved in
fractions corresponding to molecular weights lower than 40 kDa
(Fig. 4B–C–D–E), confirming that the first 42 amino acids are not
sufficient to mediate auto-aggregation of the receptor. On the
other hand, CD95(1–66)-mCherry failed to form homotrimers but
Figure 2. The PLAD is instrumental in transmission of the apoptotic signal and does not encompass residues 1 to 42 of CD95. A.
CD95-deficient CEM-IRC cells were transfected with the indicated cDNA and living cells were isolated by Ficoll gradient and lysed. For each condition,
100 mg of protein was loaded per lane and immunoblot analysis was performed using an anti-CD95 mAb (C20). Data are representative of three
independent experiments. B. Three independent CEM-IRC clones stably expressing CD95wild type, CD95(D1–42), CD95(D1–66) CD95(1–210) were selected
and the amount of CD95 construct at the plasma membrane was analyzed by flow cytometry. C. CEM-IRC cells shown in F were incubated for 24
hours with the indicated concentrations of Ig-CD95L (left panel) or 7C11 (right panel). Cell death was assessed by MTT assay. Results are given as the
means 6 SD of three independently performed experiments.
doi:10.1371/journal.pone.0046236.g002
Figure 3. Another cellular model confirms that the PLAD does not encompass residues 1 to 42 of CD95. A. The anti-mouse CD95 mAb,
clone Jo2, induces cell death by aggregating mouse CD95. If human CD95 forms a supernumerary and functional pre-associated hetero-complex with
its mouse ortholog, the Jo2-mediated apoptotic signal will be enhanced. B. For each construct, two independent BaF3 clones were selected and the
amount of human CD95 at the cell surface was assessed by flow cytometry. C. The BaF3 cells depicted in B were incubated for 24 hours with the
indicated concentration of Jo2 and cell death was assessed by MTT assay. Results are given as the means 6 SD of three independently performed
experiments.
doi:10.1371/journal.pone.0046236.g003
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aggregated as homodimer (Fig. 4B–C–D–E) since the protein was
mainly detected in fractions covering 65 to 70 kDa depending on
the gel filtration column used to resolve the native molecular masse
of the chimera. Overall, these data not only validate that the
stretch of amino acids 43 to 66 constitutes a CD95 homotypic
interaction domain, but also reveal that the region between amino
acids 67 and 158 favors the formation of CD95 quaternary
structure.
Discrepancy concerning the inclusion of the first 42 amino acids
in the PLAD may be explained by the fact that the CD95
constructs used by Ruberti’s group were generated via in vitro
translation or prokaryotic systems, neither of which are capable of
glycosylation [9]. The extracellular domain of CD95 contains two
putative glycosylation sites in the first 42 amino acids: an N-
glycosylation at Asp 32 [22] and a threonine-rich motif (Thr24 to
Thr30) that resembles O-glycosylated mucin-type sequences [23].
In agreement with previous reports showing that sialylation of
CD95 inhibited apoptotic signaling [24,25], a more recent study
demonstrated that CD95 glycosylation impairs receptor oligomer-
ization [22]. Accordingly, glycosylation of the CD95 amino-
terminal domain may inhibit the potential homotypic interaction
of the 1–42 region that was observed in unglycosylated CD95
mutants. It is noteworthy that although the chimeric CD95(1–66)-
mCherry protein contains the necessary PLAD, it fails to form
homotrimers, but rather forms homodimeric structures, suggesting
that in addition to the DD, a motif located between amino acids
67 to 158 promotes auto-aggregation of CD95, or that truncation
of the protein interferes with the ternary structure of CD95 and
reduces homotypic affinity. Using transient transfection of T-cell
lines expressing high amounts of wild-type CD95, Siegel et al.
showed that in contrast to a DD-truncated mutant, expression of
mutant in which both the first 42 amino acids and the DD (CD95-
(43–210)) were deleted did not affect CD95-mediated apoptotic
signaling. This indicates that without this amino-terminal region,
the CD95 mutant fails to form a heterotrimer with its wild-type
counterpart and thus cannot act as a dominant-negative subunit
[7]. Based on our findings, although this CD95-(43–210) construct
still encompasses the major homotypic interaction domain (amino
acids 43 to 66), a decrease in its homotypic affinity may impair its
ability to interfere with the high amounts of endogenous wild-type
CD95; thus, it fails to alter the formation of wild-type CD95
homotrimers and transmission of the apoptotic signal.
Figure 4. The CD95 self-association domain covers the residues 43 to 66. A. Schematic representation of the different CD95-mCherry
constructs. B. Supernatants from HEK cells transfected with the constructs depicted in A were fractionated by gel filtration using a S-300 HR column.
Seventeen fractions were harvested and analyzed by immunoblot analysis (anti-DsRed). C. Densitometry analyses were performed on the
immunoblots shown in B using Fiji software. For each construct, the estimated quaternary structure is depicted. D. Supernatants from HEK cells
transfected with the constructs depicted in A were fractionated by gel filtration using a S-200 HR column. Twenty-one fractions were harvested and
analyzed by immunoblot analysis (anti-DsRed). E. Densitometry analyses were performed on the immunoblots shown in D using Fiji software. For
each construct, the estimated quaternary structure is depicted.
doi:10.1371/journal.pone.0046236.g004
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Mutations in the extracellular region of CD95 represent less
than 30 percent of all mutations found in ALPS type Ia patients
and these mutations exhibit a lower clinical penetrance compared
to intracellular mutations. Nonetheless, two mutations in the
ectodomain of CD95 (C57X and D62frameshift), which abrogate
the CD95-mediated apoptotic signal despite showing no affinity
for the ligand, have been described [5]. These rare mutations shed
light on the minimal extracellular region of CD95 necessary for
auto-aggregation of the receptor. In light of recent observations
showing that CD95 participates in chronic inflammation and
tumor dissemination through non-apoptotic signaling pathways
[11,26–29], inhibiting CD95 oligomerization by interfering with
the PLAD may represent a novel therapeutic strategy able to
hamper glioma metastasis or dampen crisis in lupus patients
[11,29].
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